TrakCel design, deploy and support digital Cellular Orchestration Solutions that track and manage all the components of the Cell and Gene Therapy supply chain, helping therapy developers to deliver therapies to patients safely and efficiently for both clinical and commercial stage therapies.
For each Advance Therapy Patient journey, from sample collection through logistics, manufacturing and final treatment, TrakCel's flagship platform, OCELLOS orchestrates every step, providing a comprehensive chain of custody, chain of identity and traceability throughout. Always remembering there is a patient at the end of everything we do.
We innovate.
We unite.
We transform tomorrow.
Want to know more about how TrakCel could transform your therapy supply chain, get in touch and book a free product demo.
Join us. See the journey.
Location: United Kingdom
Employees: 51-200
Founded date: 2012
Investors 3
Mentions in press and media 6
| Date | Title | Description | Source |
| 25.01.2022 | AmerisourceBergen and TrakCel Launch Integrated Platform to ... | The integration of TrakCel’s OCELLOS and Lash Group’s Fusion aims to improve speed-to-therapy by inc... | thpartners... |
| 05.03.2021 | TrakCel Receives Strategic Investment | TrakCel, a Cardiff, Wales-based supplier of cellular orchestration solutions supporting the cell and... | finsmes.co... |
| 16.04.2018 | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s... | Section 32 is the San Diego-based venture capital firm that that Bill Maris, the former CEO of Googl... | medcitynew... |
| 19.10.2016 | TrakCel Receives an Equity Investment from Telegraph Hill Pa... | TrakCel, a Cardiff, Wales, UK-based cellular orchestration platform developer, received a multi-mill... | finsmes.co... |
| 15.10.2016 | THP invests in leading Cellular Orchestration Platform devel... | CARDIFF, WALES, UK – TrakCel, the leading provider of cellular orchestration technology to aid in th... | thpartners... |
| - | Cell-therapy startup raises $33.5M from Canaan, Bill Maris’s... | With a platform promising protection against cell-based therapy supply-chain missteps, Vineti has co... | medcitynew... |